Clinical Trial Update: Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Purinostat Mesylate for Injection in relapsed or refractory B cell–related tumors, including diffuse large B-cell lymphoma, has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Purinostat Mesylate (Purinostat Mesylate)

Snippet

Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd | Conditions: Diffuse Large B Cell Lymphoma，DLBCL | Phase 1 | Status: COMPLETED